Gene · 5889
Papers3,668
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,081 to 1,100 of 3,668
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis. | Cancers (Basel) | 2022 | 35454841 | PubTator, text mining | PubMed |
| Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy. | Diagnostics (Basel) | 2022 | 35453890 | PubTator, text mining | PubMed |
| Perspectives on Ovarian Cancer 1809 to 2022 and Beyond. | Diagnostics (Basel) | 2022 | 35453839 | PubTator, text mining | PubMed |
| Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective. | Mol Genet Genomics | 2022 | 35451682 | PubTator, text mining | PubMed |
| Germline testing and genetic counselling in prostate cancer. | Nat Rev Urol | 2022 | 35449224 | PubTator, text mining | PubMed |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice. | Curr Oncol | 2022 | 35448190 | PubTator, text mining | PubMed |
| Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes. | J Natl Cancer Inst | 2022 | 35445726 | PubTator, text mining | PubMed |
| Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis. | EBioMedicine | 2022 | 35439677 | PubTator, text mining | PubMed |
| Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer. | Salud Publica Mex | 2022 | 35438911 | PubTator, text mining | PubMed |
| SMARCA2/BRM-Deficient Undifferentiated/Rhabdoid Carcinoma of Unknown Primary Site. | Case Rep Oncol | 2022 | 35431870 | PubTator, text mining | PubMed |
| Clinical application of liquid biopsy in cancer patients. | BMC Cancer | 2022 | 35428225 | PubTator, text mining | PubMed |
| Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. | Cancer Res | 2022 | 35425960 | PubTator, text mining | PubMed |
| Hereditary Gynecologic Cancer Syndromes - A Narrative Review. | Onco Targets Ther | 2022 | 35422633 | PubTator, text mining | PubMed |
| Breast cancer in the era of integrating "Omics" approaches. | Oncogenesis | 2022 | 35422484 | PubTator, text mining | PubMed |
| The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches. | Prostate Cancer Prostatic Dis | 2022 | 35422101 | PubTator, text mining | PubMed |
| Global characterization of extrachromosomal circular DNAs in advanced high grade serous ovarian cancer. | Cell Death Dis | 2022 | 35418185 | PubTator, text mining | PubMed |
| Recurrent Acromegaly in a Patient With a CHEK2 Mutation. | AACE Clin Case Rep | 2022 | 35415223 | PubTator, text mining | PubMed |
| A positive feedback loop: RAD18-YAP-TGF-β between triple-negative breast cancer and macrophages regulates cancer stemness and progression. | Cell Death Discov | 2022 | 35413945 | PubTator, text mining | PubMed |
| Holliday junction resolution by At-HIGLE: an SLX1 lineage endonuclease from Arabidopsis thaliana with a novel in-built regulatory mechanism. | Nucleic Acids Res | 2022 | 35412622 | PubTator, text mining | PubMed |
| Present status of germline findings in precision medicine for Japanese cancer patients: issues in the current system. | Jpn J Clin Oncol | 2022 | 35411369 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5889/papers?page=55